Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article

Ghaffari, Javad; Ghaffari, Negar

doi:10.5812/jpr.11507

Cited by 2 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other treatment options for CHS include chemotherapy, a high dosage of methylprednisolone, and IL-2 administration. Allogenic hematopoietic stem cell transplantation (HSCT) is the most successful approach before the patient enters the accelerated phase [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Management of Severe Neutropenia in a Child With Chediak-Higashi Syndrome Using Granulocyte-Colony Stimulating Factor (G-CSF): A Case Report

Almesfer,

Alradhi,

Alamr

et al. 2023

Cureus

View full text Add to dashboard Cite

Chediak-Higashi syndrome (CHS) is a congenital immunodeficiency disorder characterized by recurrent bacterial infections, oculocutaneous albinism, and abnormal intracellular protein transport. The incidence of CHS is rare, with approximately 500 cases reported so far. One of the key immunological features of CHS is neutropenia. The management of CHS includes supportive treatment, chemotherapy, methylprednisolone, IL-2 administration, and hematopoietic stem cell transplantation (HSCT). However, neutropenia can persist even after these treatments. This case report presents the successful management of severe neutropenia in an 8-year-old girl diagnosed with CHS. The patient exhibited classic CHS features, including hypopigmentation and recurrent infections. Initial treatment with antibiotics led to the resolution of the fever, but severe neutropenia persisted. Granulocyte-colony stimulating factor (G-CSF) therapy was initiated, which resulted in a substantial increase in the absolute neutrophil count (ANC) with no adverse effects. Throughout treatment with G-CSF, the patient remained stable. The patient was finally referred to the tertiary care center for consideration of bone marrow transplantation. This case highlights the potential safety and efficacy of G-CSF in managing CHS-associated neutropenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Management of Severe Neutropenia in a Child With Chediak-Higashi Syndrome Using Granulocyte-Colony Stimulating Factor (G-CSF): A Case Report

Almesfer,

Alradhi,

Alamr

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…An SR of omalizumab reviewed eight studies involving children with moderate–severe AE 11 . However, only one study was an RCT; the rest were cohort studies, case series and case reports, and the number of participants in each study was no greater than 11.…”

Section: Omalizumabmentioning

confidence: 99%

“…An SR of omalizumab reviewed eight studies involving children with moderate-severe AE. 11 However, only one study was an RCT; the rest were cohort studies, case series and case reports, and the number of participants in each study was no greater than 11. Although the authors concluded that omalizumab 'decreases SCORAD [SCORing Atopic Dermatitis] in all of severe AE', this assertion was based on small, uncontrolled and underpowered studies.…”

Section: Omalizumabmentioning

confidence: 99%

What’s new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies

Olabi¹,

Worboys²,

Garland

et al. 2020

Clin. Exp. Dermatol.

View full text Add to dashboard Cite

Summary This review forms part of an annual update series on atopic eczema (AE), where systematic reviews (SRs) are gathered and appraised to provide a summary of key recent research findings. The focus of this article is systemic therapies used in AE, while a review on prevention and topical therapies is provided in Part 1. In total, 17 SRs on various systemic treatments used in AE were first published or indexed in 2018. There is a lack of evidence to support vitamin D supplementation, montelukast and naltrexone in AE treatment. The adverse effects of systemic corticosteroids are the main barrier to their use, and there is also a lack of data to determine the optimal delivery and duration of treatment with them. Of other immunosuppressants, ciclosporin has the most robust evidence of efficacy. Biologic therapies in AE treatment are being increasingly investigated, and to date, the greatest quantity of data and evidence of efficacy relates to dupilumab. The most commonly reported adverse effects are injection‐site reactions and conjunctivitis. Other biologics showing some evidence of efficacy include nemolizumab, lebrikizumab and tralokinumab, although further data are needed. There are currently insufficient data on oral small molecules, including Janus kinase inhibitors, in the treatment of AE. A Cochrane review on probiotics showed no significant benefit, and SRs and meta‐analyses on complementary and alternative medicines, including probiotics, in paediatric AE demonstrated significant heterogeneity, thereby limiting their interpretation. This summary of recent SRs provides up‐to‐date evidence for clinicians on systemic therapies in AE.

show abstract

Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article

Cited by 2 publications

References 13 publications

Management of Severe Neutropenia in a Child With Chediak-Higashi Syndrome Using Granulocyte-Colony Stimulating Factor (G-CSF): A Case Report

Management of Severe Neutropenia in a Child With Chediak-Higashi Syndrome Using Granulocyte-Colony Stimulating Factor (G-CSF): A Case Report

What’s new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies

Contact Info

Product

Resources

About